For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...

Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...

Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...

Avendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...

Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...

Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band...

Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...

Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...

India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With ...

India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...

India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...

Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...

We are constructive on markets and believe the recent correction offers a good entry point to start accumulation for long term wealth gener...

Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...

Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....

The issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...

Jubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore ...